Your browser doesn't support javascript.
SARS-CoV-2 Variant Exposures Elicit Antibody Responses With Differential Cross-Neutralization of Established and Emerging Strains Including Delta and Omicron.
Laurie, Matthew T; Liu, Jamin; Sunshine, Sara; Peng, James; Black, Douglas; Mitchell, Anthea M; Mann, Sabrina A; Pilarowski, Genay; Zorn, Kelsey C; Rubio, Luis; Bravo, Sara; Marquez, Carina; Sabatino, Joseph J; Mittl, Kristen; Petersen, Maya; Havlir, Diane; DeRisi, Joseph.
  • Laurie MT; Department of Biochemistry and Biophysics, University of California San Francisco, San Francisco, California, USA.
  • Liu J; Department of Biochemistry and Biophysics, University of California San Francisco, San Francisco, California, USA.
  • Sunshine S; University of California Berkeley-University of California San Francisco Graduate Program in Bioengineering, Berkeley, California, USA.
  • Peng J; Department of Biochemistry and Biophysics, University of California San Francisco, San Francisco, California, USA.
  • Black D; Department of Medicine, University of California San Francisco, San Francisco, California, USA.
  • Mitchell AM; Department of Medicine, University of California San Francisco, San Francisco, California, USA.
  • Mann SA; Department of Biochemistry and Biophysics, University of California San Francisco, San Francisco, California, USA.
  • Pilarowski G; Chan Zuckerberg Biohub, San Francisco, California, USA.
  • Zorn KC; Department of Biochemistry and Biophysics, University of California San Francisco, San Francisco, California, USA.
  • Rubio L; Chan Zuckerberg Biohub, San Francisco, California, USA.
  • Bravo S; The Public Health Company, Oakland, California, USA.
  • Marquez C; Unidos en Salud, San Francisco, California, USA.
  • Sabatino JJ; Department of Biochemistry and Biophysics, University of California San Francisco, San Francisco, California, USA.
  • Mittl K; Department of Medicine, University of California San Francisco, San Francisco, California, USA.
  • Petersen M; Unidos en Salud, San Francisco, California, USA.
  • Havlir D; Department of Medicine, University of California San Francisco, San Francisco, California, USA.
  • DeRisi J; Weill Institute for Neurosciences, Department of Neurology, San Francisco, California, USA.
J Infect Dis ; 225(11): 1909-1914, 2022 06 01.
Article in English | MEDLINE | ID: covidwho-1606029
ABSTRACT
The wide spectrum of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants with phenotypes impacting transmission and antibody sensitivity necessitates investigation of immune responses to different spike protein versions. Here, we compare neutralization of variants of concern, including B.1.617.2 (delta) and B.1.1.529 (omicron), in sera from individuals exposed to variant infection, vaccination, or both. We demonstrate that neutralizing antibody responses are strongest against variants sharing certain spike mutations with the immunizing exposure, and exposure to multiple spike variants increases breadth of variant cross-neutralization. These findings contribute to understanding relationships between exposures and antibody responses and may inform booster vaccination strategies.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Randomized controlled trials Topics: Vaccines / Variants Limits: Humans Language: English Journal: J Infect Dis Year: 2022 Document Type: Article Affiliation country: Infdis

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Randomized controlled trials Topics: Vaccines / Variants Limits: Humans Language: English Journal: J Infect Dis Year: 2022 Document Type: Article Affiliation country: Infdis